Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/16—Otologicals

Definitions

• the invention relates to the use of adamantane derivatives of the formula ##STR2##
• R3 and R4 are identical or different and can be hydrogen, straight-chained or branched alkyl groups having between 1 and 6 carbon atoms, cycloalkyl groups having 5 or 6 carbon atoms or a phenyl group, and in which R5 is hydrogen or a straight-chained or branched alkyl group having between 1 and 6 carbon atoms.
• adamantane derivatives falling under the cited general formula I for the therapy of certain diseases is already known.
• the dopamine-related influence of amantadine (1-adamantanamine) is described in a series of publications.
• an antiviral effect of certain amino-adamantanes has been demonstrated.
• EP B1-392059 shows the use of adamantane derivatives in preventing and treating cerebral ischaemia.
• adamantane derivatives having the formulua I as described above can protectively prevent destruction of brain cells following an ischaemia, the adamantane derivatives being employed as antagonists for the NDMA receptor channels of the nerve cells.
• both general and special methods of producing adamantane derivatives falling under the above-cited formula I are described.
• tinnitus diseases of the inner ear are widespread, especially as regards diseases or disturbances in which subjective noise in the ear, so-called tinnitus occurs. It is estimated that in Germany alone roughly 6 million people suffer from tinnitus. In roughly 800,000 cases the tinnitus is so pronounced that these patients need intensive treatment by a physician, due to the patient being seriously handicapped by tormenting ear noise. At this time no reliable therapy is available.
• the object of the invention is thus to define a possibility of treating diseases of the inner ear, more particularly in the case of tinnitus, with which a perceptible compensation of the symptoms associated with the disease is achieved. More particularly, the tormenting ear noise is made to disappear or diminished to such a degree that the patient reattains his normal quality of life.
• adamantane derivatives can be used in the case of inner ear diseases in which troublesome ear noise, so-called tinnitus occurs, especially in the case of treating such forms of tinnitus as chronic tinnitus, subacute tinnitus or also acute permanent tinnitus, since it is just these patients that require intensive therapy.
• the so-called positive recruitment is a phenomenon in audiometry when a comparison of the loudness is undertaken in the case of one-sided deafness.
• positive recruitment a slight amplification is needed in the ear impaired in hearing to prompt the same loudness sensitivity as for the healthy ear, i.e. the loss in hearing is compensated by increasing loudness.
• otoacoustic emissions are noise events occurring in the external canal having to do with the condition of the middle ear or inner ear. Otoacoustic emissions may occur spontaneously, i.e. without the ear receiving external stimulation or also being evoked externally, for example with the aid of a sound emitter.
• adamantane derivatives directly affect other receptors present on the outer hair cells, for example, purine receptors and acetylcholine receptors.
• adamantane derivatives may obstruct the cation transporter relaying the return transport of neurotransmitters from the synaptic gap in the presynapse, resulting in a depletion of the neurotransmitter in the efferent presynapsis and thus (indirectly) in reduced stimulation of receptors.
• This mechanism developing at the presynapse, i.e. before the synaptic gap could be effective in the form described along the full hearing passage up to the auditory cortex.
• Formula I adamantane derivatives can be employed as described by the formula or preferably in the form of their pharmaceutically acceptable salts, hydrobromides, sulphates, acetates, succinates, tartrates, for example, or, more particularly, the hydrochlorides belonging to these additional salts.
• other salts as usual may be represented and employed.
• the quantity of the adamantane derivatives used is normally not critical, it materializing for the person skilled in the art as usual from values gained from experience or by implementing trial and error tests prior to application. Expediently the quantities used are typically between approximately 0.01 and approximately 100 mg/kg body-weight, preferably from approximately 0.1 to approximately 1 mg/kg body-weight, whereby quantities of approximately 0.1 to approximately 0.5 mg/kg body-weight are preferred in the last-mentioned range.
• the invention covers the use of all formula I amino adamantanes for treatment of diseases of the inner ear.
• Examples of such compounds are listed, for example, in EP-B1-392059, the contents of which are accordingly made that of the present description.
• Preferred formula I compounds are those in which R1 and R2 signify hydrogen H and compounds in which R5 and, more particularly, additionally R1 and R2 signify the hydrogen residue.
• residues R3 and R4 are optionally a methyl or ethyl residue.
• One particularly preferred compound employable in accordance with the invention is memantine, i.e. 1-amino-3.5-dimethyladamantane or the hydrochloride thereof, memantine HCl.
• This compound or its salt is particularly suitable for the treatment of diseases of the inner ear, especially in treating tinnitus.
• the invention otherwise involves also a method of treating diseases of the inner ear in which an effective quantity of an adamantane derivative having the general formula I is administered.
• a corresponding method is suitable, more particularly, for the treatment of tinnitus, reference being made to the particular aspects of the administration already described as regards the compounds employable and the quantities used.
• the treated group of patients totalling 104 in number comprised patients having chronic tinnitus, subacute tinnitus and acute permanent tinnitus.
• the medicament used was the preparation Akatinol Memantine" of the Company Merz & Co., GmbH & Co, Frankfurt am Main.
• the active substance of this preparation is memantine HCL along with lactose, magnesium stearate, polyaminoethacrylate, among other things, as the usual pharmaceutical media and expedients.
• Such pharmaceutical media and expedients may be present, of course, as usual in all embodiments of the invention so that they can be administered, for example, in the form of tablets, dragees, sterile solutions or injections.
• the patients were administered the active substance initially by infusions. Up to the 5th day they received typically a quantity of 10 mg/d (daily), this quantity being increased to 20 mg/d as of the 6th day. Depending on the patient concerned an abrupt improvement in the complaints occurred between the 6th and 8th day in the group of those responding to treatment.
• the infusion treatment was continued until the 10th day with a quantity of 20 mg/d.
• the dose was higher, without, however, ever exceeding a quantity of maximally 30 mg/d.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7768513

Family Applications (1)

Country Status (14)

Cited By (34)

Families Citing this family (8)

Citations (5)

• 1995
  • 1995-08-02 DE DE19528388A patent/DE19528388A1/de not_active Withdrawn
• 1996
  • 1996-07-31 JP JP50725097A patent/JP3568039B2/ja not_active Expired - Fee Related
  • 1996-07-31 AU AU67882/96A patent/AU719018B2/en not_active Ceased
  • 1996-07-31 ES ES96112325T patent/ES2116801T3/es not_active Expired - Lifetime
  • 1996-07-31 EP EP97122113A patent/EP0834310A1/de not_active Withdrawn
  • 1996-07-31 US US09/011,085 patent/US6066652A/en not_active Expired - Lifetime
  • 1996-07-31 WO PCT/EP1996/003360 patent/WO1997004762A1/de active IP Right Grant
  • 1996-07-31 IL IL12314296A patent/IL123142A/en not_active IP Right Cessation
  • 1996-07-31 DE DE59600105T patent/DE59600105D1/de not_active Expired - Lifetime
  • 1996-07-31 DE DE19680619T patent/DE19680619D2/de not_active Expired - Lifetime
  • 1996-07-31 DK DK96112325T patent/DK0759295T3/da active
  • 1996-07-31 CN CNB961966505A patent/CN1142775C/zh not_active Expired - Fee Related
  • 1996-07-31 EP EP96112325A patent/EP0759295B1/de not_active Expired - Lifetime
  • 1996-07-31 BR BR9609950A patent/BR9609950A/pt not_active Application Discontinuation
  • 1996-07-31 KR KR10-1998-0700738A patent/KR100393296B1/ko not_active IP Right Cessation
  • 1996-07-31 PL PL96324795A patent/PL324795A1/xx unknown
  • 1996-07-31 AT AT96112325T patent/ATE163545T1/de active

Patent Citations (6)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events